Arrowhead Research Corp (ARWR) is Downgraded by William Blair to Mkt Perform

Arrowhead Research Corp (ARWR) was Downgraded by William Blair to ” Mkt Perform”. Earlier the firm had a rating of “Outperform ” on the company shares. William Blair advised their investors in a research report released on Nov 30, 2016.

Many Wall Street Analysts have commented on Arrowhead Research Corp. Shares were Reiterated by Chardan Capital Markets on Nov 10, 2016 to “Buy” and Lowered the Price Target to $ 8 from a previous price target of $10 .

On the company’s financial health, Arrowhead Research Corp reported $-0.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.36. The company had revenue of $39.58 million for the quarter, compared to analysts expectations of $.05 million. The company’s revenue was down -68.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.27 EPS.

Arrowhead Research Corp closed down -0.07 points or -1.57% at $4.39 with 30,39,263 shares getting traded on Tuesday. Post opening the session at $4.46, the shares hit an intraday low of $4.37 and an intraday high of $4.5 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

In a different news, on Oct 18, 2016, Douglas B Given (director) sold 12,000 shares at $6.72 per share price. According to the SEC, on Aug 24, 2016, Kenneth Allen Myszkowski (Chief Financial Officer) sold 20,000 shares at $8.00 per share price. On Jan 14, 2015, Mauro Ferrari (director) purchased 2,300 shares at $6.90 per share price, according to the Form-4 filing with the securities and exchange commission.

Arrowhead Research Corporation is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. The Company’s products include ARC-520 ARC-521 ARC-AAT ARC-F12 ARC-HIF2 and ARC-LPA. ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. ARC-AAT is an unlocked nucleobase analog-containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its Dynamic Polyconjugate platform is an RNAi delivery system that promotes high levels of target gene knockdown. ARC-F12 is an RNAi-based therapeutic designed to reduce the production of factor 12 with the goal of providing a prophylactic treatment for hereditary angioedema and thromboembolic diseases. ARC-LPA is an RNAi-based therapeutic designed to reduce production of apolipoprotein A. ARC-HIF2 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 2a.

Arrowhead Research Corp

Leave a Reply

Arrowhead Research Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Arrowhead Research Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.